Life Sciences IPOs Have Biggest Month in 13 Years, Burrill & Company says June 04, 2013 | Press Release
Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press ReleaseSee all News
Michael KeyoungManaging Director, Pan-Asia
Dr. Keyoung has more than 15 years of healthcare and life sciences experience through his role as scientist, surgeon, consultant and investor. At Burrill & Company, Dr. Keyoung manages Burrill’s Pan-Asia Equity Fund, oversees Burrill’s U.S. and European public portfolio companies and leads our Pan-Asia transaction business as well as our global arbitrage efforts across multiple countries in Asia. Previously, Dr. Keyoung was a co-founder of a life sciences healthcare investment partnership in New York. Dr. Keyoung also served as an advisor and consultant leading life sciences venture capital firms, medical devices, pharma, and biotechnology companies. Previously, Dr. Keyoung was a Howard Hughes Medical Institute fellow and received his clinical surgical training at University of California, San Francisco and biomedical fellowship at Memorial Sloan Kettering Institute and Rockefeller University in New York. Dr. Keyoung performed preclinical drug discovery research for Aventis (now Sanofi-Aventis) and Merck while at Cornell and participated in cutting-edge translational clinical trials at leading academic centers. As National Institute of Health-Medical Scientist Training Program scholarship recipient, Dr. Keyoung received both his Medical Doctorate and Doctor of Philosophy degrees in Neuroscience and Neurology from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center. Dr. Keyoung has over 35 articles, book chapters and presentations in publications such as Nature Biotechnology and Nature Medicine.
Dr. Keyoung has served on the Board of Directors at New York County Medical Society and Board of Overseers at the Cornell University-Weill Medical College in New York and currently serves on the boards of private biopharma companies and organizations in the U.S. and in Asia.